ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Immunology
インパクトファクター: 1.352 5年インパクトファクター: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN 印刷: 1040-8401
ISSN オンライン: 2162-6472

巻:
巻 39, 2019 巻 38, 2018 巻 37, 2017 巻 36, 2016 巻 35, 2015 巻 34, 2014 巻 33, 2013 巻 32, 2012 巻 31, 2011 巻 30, 2010 巻 29, 2009 巻 28, 2008 巻 27, 2007 巻 26, 2006 巻 25, 2005 巻 24, 2004 巻 23, 2003 巻 22, 2002 巻 21, 2001 巻 20, 2000 巻 19, 1999 巻 18, 1998 巻 17, 1997 巻 16, 1996 巻 15, 1995 巻 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2018027460
pages 433-451

IL-7 and Its Beneficial Role in Sepsis-Induced T Lymphocyte Dysfunction

Charles de Roquetaillade
EA7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)", Université Claude Bernard Lyon 1, Lyon, France
Guillaume Monneret
EA7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)", Université Claude Bernard Lyon 1, Lyon, France; Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France
Morgane Gossez
EA7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)", Université Claude Bernard Lyon 1, Lyon, France; Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France
Fabienne Venet
EA7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)", Université Claude Bernard Lyon 1, Lyon, France; Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France

要約

Sepsis, defined as life-threatening organ dysfunction caused by dysregulated host response to infection, has recently been acknowledged as a worldwide health priority. Sepsis remains the leading cause of mortality in intensive care units and accounts for 6 million deaths every year. Few therapeutic options targeting host immune response in sepsis have demonstrated their efficacy so far. Increasing evidence suggests that a profound immune suppression develops following sepsis, affecting innate and adaptive immune response, of which intensity and duration is associated with increased risk of death and nosocomial infection. Immunostimulant treatments are thus now evaluated in sepsis, and recombinant human IL-7 (rhIL-7) represents a promising candidate. rhIL-7 has been evaluated in several clinical trials in patients with altered lymphocytic responses (HIV infection, hematopoietic stem cell transplantation, and cancer). Recent studies in animal models and in patients' samples ex vivo demonstrated its efficacy in improving sepsis-induced T cell alterations. Finally, the first clinical trial evaluating rhIL-7 in septic shock patients has just been published. This review will discuss the use of rhIL-7 to treat sepsis-induced T cell dysfunction by introducing the pathophysiology of sepsis and sepsis-related lymphocyte alterations before focusing on rhIL-7 and its potential use of as a therapeutic intervention in patients.


Articles with similar content:

Pathogenesis of Multiple Organ Failure in Sepsis
Critical Reviews™ in Immunology, Vol.35, 2015, issue 4
Alexander Zarbock, Jan Rossaint
Antigen-Specific Tolerance in Immunotherapy of Th2-Associated Allergic Diseases
Critical Reviews™ in Immunology, Vol.33, 2013, issue 5
Paul J. Bryce, Charles B. Smarr, Stephen D. Miller
Regulation Generation: The Suppressive Functions of Human Regulatory T Cells
Critical Reviews™ in Immunology, Vol.32, 2012, issue 1
Kevin D. Cooper, Thomas S. McCormick, Wendy A. Goodman
Understanding Lung Immunopathology Caused by the Human Metapneumovirus: Implications for Rational Vaccine Design
Critical Reviews™ in Immunology, Vol.35, 2015, issue 3
Claudia A. Riedel, Christian E. Palavecino, Alexis M. Kalergis, Susan M. Bueno, Pablo F. Cespedes, Margarita K. Lay
CD4+ T Cell Activation During the Newborn Period: Barriers Against and Pathways Toward Th1 Immunity
Critical Reviews™ in Immunology, Vol.38, 2018, issue 1
Christina L. Lancioni, Luke S. Uebelhoer